SL327featured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406197
CAS#:305350-87-2
Description:SL327 is a MEK inhibitor. SL327 blocks acquisition but not expression of lithium-induced conditioned place aversion: a behavioral and immunohistochemical study. SL327 had no affect on acquisition, expression, or extinction of EtOH-induced CPP in mice despite causing significant reduction of pERK levels in multiple brain regions. Additionally, although SL327 caused a generalized depression of locomotor activity, it did not prevent the development of EtOH-sensitization.
Price and Availability
SL327, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406197Name: SL327CAS#: 305350-87-2Chemical Formula: C16H12F3N3SExact Mass: 335.0704Molecular Weight: 335.35Elemental Analysis: C, 57.31; H, 3.61; F, 17.00; N, 12.53; S, 9.56
Synonym:SL327; SL 327; SL-327.
IUPAC/Chemical Name:(E)-3-amino-3-((4-aminophenyl)thio)-2-(2-(trifluoromethyl)phenyl)acrylonitrile
InChi Key:JLOXTZFYJNCPIS-SQFISAMPSA-N
InChi Code:InChI=1S/C16H12F3N3S/c17-16(18,19)14-4-2-1-3-12(14)13(9-20)15(22)23-11-7-5-10(21)6-8-11/h1-8H,21-22H2/b15-13-
SMILES Code:N#C/C(C1=CC=CC=C1C(F)(F)F)=C(N)/SC2=CC=C(N)C=C2
Technical Data
Additional Information
References
1: Longoni R, Spina L, Vinci S, Acquas E. The MEKinhibitor SL327 blocks acquisition but not expression of lithium-induced conditioned placeaversion: a behavioral and immunohistochemical study. Psychopharmacology (Berl).2011 Jul;216(1):63-73. doi: 10.1007/s00213-011-2192-9. Epub 2011 Feb 11.PubMed PMID: 21312031.
我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是：建成全球最大的小分子抗癌药库 ，品种最多最全、质量最好最可靠。美帝药库的宗旨是：客户第一；质量第一；信誉第一；创新第一。
